These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 36248883)
1. Neutralization effect of plasma from vaccinated COVID-19 convalescents on SARS-CoV-2 Omicron variants. Xie Y; Liu L; Wang J; Zheng Y; Luo C; Ni W; He Z; Zhao X; Liu Y; He Y; Zheng S; Li L; Liu Z Front Immunol; 2022; 13():975533. PubMed ID: 36248883 [TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays. Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H Front Immunol; 2023; 14():1170759. PubMed ID: 37180152 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants. Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents. Zheng Y; Pan J; Jin M; Wang J; Tung TH; Chen S; Bi X; Zhou K; Chen M; Wang D; Li J; Shen B; Ying L Int Immunopharmacol; 2023 Jun; 119():110151. PubMed ID: 37044040 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 evolves to reduce but not abolish neutralizing action. Zhang Y; Ndzouboukou JB; Lin X; Hou H; Wang F; Yuan L; Gan M; Yao Z; Fu H; Cao J; Fan X J Med Virol; 2023 Jan; 95(1):e28207. PubMed ID: 36217880 [TBL] [Abstract][Full Text] [Related]
6. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice. Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319 [TBL] [Abstract][Full Text] [Related]
7. Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum. Liang D; Zhang G; Huang M; Wang L; Hong W; Li A; Liang Y; Wang T; Lu J; Ou M; Ren Z; Lu H; Zheng R; Cai X; Pan X; Xia J; Ke C Pathogens; 2022 Dec; 11(12):. PubMed ID: 36558864 [TBL] [Abstract][Full Text] [Related]
8. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Carreño JM; Alshammary H; Tcheou J; Singh G; Raskin AJ; Kawabata H; Sominsky LA; Clark JJ; Adelsberg DC; Bielak DA; Gonzalez-Reiche AS; Dambrauskas N; Vigdorovich V; ; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F Nature; 2022 Feb; 602(7898):682-688. PubMed ID: 35016197 [TBL] [Abstract][Full Text] [Related]
9. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization. Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314 [TBL] [Abstract][Full Text] [Related]
10. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. Sullivan DJ; Franchini M; Joyner MJ; Casadevall A; Focosi D Nat Commun; 2022 Oct; 13(1):6478. PubMed ID: 36309490 [TBL] [Abstract][Full Text] [Related]
11. Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant. Villas-Boas LS; Paula AV; Silva ARD; Paiao HGO; Tozetto-Mendoza TR; Manuli ER; Leal FE; Ferraz ABC; Sabino EC; Bierrenbach AL; Witkin SS; Mendes-Correa MC Clinics (Sao Paulo); 2022; 77():100068. PubMed ID: 35767900 [TBL] [Abstract][Full Text] [Related]
12. Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron. Zhu KL; Gao HX; Yao L; Rong J; Yang L; Zhang Z; Jiang P; Duan LJ; Wang GL; Dai EH; Ma MJ J Infect Dis; 2022 Nov; 226(9):1551-1555. PubMed ID: 35429398 [TBL] [Abstract][Full Text] [Related]
13. Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants. Sun H; Xu J; Zhang G; Han J; Hao M; Chen Z; Fang T; Chi X; Yu C Viruses; 2022 Jun; 14(6):. PubMed ID: 35746803 [TBL] [Abstract][Full Text] [Related]
14. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer. Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918 [TBL] [Abstract][Full Text] [Related]
15. Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination. Wang M; Zhou B; Fan Q; Zhou X; Liao X; Lin J; Ma Z; Dong J; Wang H; Ge X; Ju B; Zhang Z Emerg Microbes Infect; 2023 Dec; 12(1):2151381. PubMed ID: 36444724 [TBL] [Abstract][Full Text] [Related]
16. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. Syed AM; Ciling A; Taha TY; Chen IP; Khalid MM; Sreekumar B; Chen PY; Kumar GR; Suryawanshi R; Silva I; Milbes B; Kojima N; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Spraggon L; Tabata T; Ott M; Doudna JA Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2200592119. PubMed ID: 35858386 [TBL] [Abstract][Full Text] [Related]
17. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination. Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152 [TBL] [Abstract][Full Text] [Related]
18. Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination. Kurahashi Y; Furukawa K; Sutandhio S; Tjan LH; Iwata S; Sano S; Tohma Y; Ohkita H; Nakamura S; Nishimura M; Arii J; Kiriu T; Yamamoto M; Nagano T; Nishimura Y; Mori Y J Infect Dis; 2022 Oct; 226(8):1391-1395. PubMed ID: 35512332 [TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors. Franchini M; Focosi D; Mengoli C; Percivalle E; Sammartino JC; Ferrari A; Zani M; Glingani C; Baldanti F Transfusion; 2022 Jun; 62(6):1171-1176. PubMed ID: 35426131 [TBL] [Abstract][Full Text] [Related]
20. Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant. Sokal A; Broketa M; Barba-Spaeth G; Meola A; Fernández I; Fourati S; Azzaoui I; de La Selle A; Vandenberghe A; Roeser A; Bouvier-Alias M; Crickx E; Languille L; Michel M; Godeau B; Gallien S; Melica G; Nguyen Y; Zarrouk V; Canoui-Poitrine F; Noizat-Pirenne F; Megret J; Pawlotsky JM; Fillatreau S; Simon-Lorière E; Weill JC; Reynaud CA; Rey FA; Bruhns P; Chappert P; Mahévas M Immunity; 2022 Jun; 55(6):1096-1104.e4. PubMed ID: 35483354 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]